A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AFICAMTEN COMPARED TO PLACEBO IN ADULTS WITH SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Study of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Sponsor: Cytokinetics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAU8685
U.S. Govt. ID: NCT06081894
Contact: Austin Nguonly, MSc: 212-305-1368 / asn2143@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the effects of Aficamten and placebo on health status and exercise capacity in participants with non-obstructive hypertrophic cardiomyopathy (nHCM). Participation in this research will involve up to 13 visits to the study site. The research study will last between 46 weeks (10.5 months) to at most 82 weeks (19 months). This time estimate includes the screening period(up to 6 weeks) to evaluate if you can participate in the study, the treatment period (36 to 72 weeks), and the follow-up period (of 4 weeks after the last treatment).
Investigator
Shepard Weiner, MD
Do You Qualify?
Have you been diagnosed with non-obstructive hypertrophic cardiomyopathy (nHCM)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Austin Nguonly, MSc
asn2143@cumc.columbia.edu
212-305-1368